Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT

Dr. Nayruz Knaana

Status: Unknown

Conditions: Neuroendocrine Tumors

Study type: Observational

Funder types: Other

Identifiers

NCT04622631

SHEBA-20- 6260-NK-CTIL

Details and patient eligibility

About

the investigators will follow up after patients with neuroendocrine tumors who undergo PRRT treatment and evaluate the response for treatment using PET/CT with different tracers

Full description

patients with suspected or biopsy proven NET will undergo imaging using a Combination of 18F- FDG , 18F-DOPA and 68Ga-DOTATATE PET/CT before the stat of PRRT . after two cycles of treatment another two PET/CT are done using 18F- FDG and 18F-DOPA and about 6-8 weeks from last treatment the patient will undergo PET/CT using 18F-DOPA .

Enrollment: 80 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient with neuroendocrine tumor
• eligible for PRRT

Exclusion criteria

• younger than 18 years old
• pregnancy

Trial design

80 participants in 2 patient groups

PRRT positive

Description:

patients who have good response to prrt treatment - the tumor and/or the metastatic disease show no uptake/activity on PET-CT scans

PRRT negative

Description:

no response to PRRT treatment